Ezetimibe-associated adverse effects: What the clinician needs to know

International Journal of Clinical Practice

Volumn 62, Issue 1, 2008, Pages 88-96

  Florentin, M ^a   Liberopoulos, E N ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTACID AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CAFFEINE; CIMETIDINE; COLESEVELAM; COLESTYRAMINE; CREATINE KINASE; DEXTROMETHORPHAN; DIGOXIN; DRUG METABOLIZING ENZYME; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GLIPIZIDE; GLUCURONOSYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIDAZOLAM; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; ORGANIC ANION TRANSPORTER 2; PHYTOSTEROL; PLACEBO; SIMVASTATIN; TOLBUTAMIDE; TRIACYLGLYCEROL; UNINDEXED DRUG; WARFARIN;

ACUTE PANCREATITIS; ADVERSE OUTCOME; ANTIBODY PRODUCTION; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CARCINOMA; CATARACT; CHOLELITHIASIS; CHOLESTEROL SYNTHESIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; FATIGUE; FOLLOW UP; GALLSTONE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GYNECOMASTIA; HAIR LOSS; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPOTENCE; INSOMNIA; KIDNEY DISEASE; LIPID BLOOD LEVEL; LIVER; LIVER FUNCTION TEST; LIVER TOXICITY; LUPUS LIKE SYNDROME; MEDLINE; MONOTHERAPY; MYOGLOBINURIA; MYOPATHY; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN MANIFESTATION; SMALL INTESTINE; SUICIDE; THROMBOSIS; WEAKNESS;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG INTERACTIONS; HUMANS; HYPERCHOLESTEROLEMIA; LIVER DISEASES; MUSCULAR DISEASES; TREATMENT OUTCOME;

EID: 37349057032     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01592.x     Document Type: Review

References (91)

1. American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas : American Heart Association, 1999.
2. World Health Organization. World Health Report. Report of the Director-General. Geneva : WHO, 1998.
3. World Health Statistics 2007. http://www.who.int/statistics (accessed 29 May 2007).
4. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78.
5. Kiortsis DN, Filippatos TD, Mikhailidis DP et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2006 Epub ahead of print.
6. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002 11 : 1587 604.
7. Altmann SW, Davis HR Jr., Zhu LJ et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004 303 : 1201 4.
8. Davis HR Jr., Zhu LJ, Hoos LM et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004 279 : 33586 92.
9. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002 106 : 1943 8.
10. Hildemann SK, Barho C, Karmann B et al. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin 2007 23 : 713 9.
11. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 2007 23 : 767 75.
12. Kosoglou T, Meyer I, Veltri EP et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002 54 : 309 19.
13. Kosoglou T, Statkevich P, Fruchart JC et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004 20 : 1197 207.
14. Kosoglou T, Statkevich P, Meyer I et al. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin 2004 20 : 955 65.
15. Kosoglou T, Statkevich P, Yang B et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004 20 : 1185 95.
16. Reyderman L, Kosoglou T, Cutler DL et al. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Curr Med Res Opin 2005 21 : 1171 9.
17. Moon YS, Chun P, Chung S. Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia. Drugs Today (Barc) 2007 43 : 35 45.
18. Jelesoff NE, Ballantyne CM, Xydakis AM et al. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract 2006 12 : 159 64.
19. Rivers SM, Kane MP, Busch RS et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007 13 : 11 6.
20. Farnier M, Roth E, Gil-Extremera B et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007 153 : 335.e1 8.
21. McKenney JM, Farnier M, Lo KW et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006 47 : 1584 7.
22. Daskalopoulou SS, Mikhailidis DP. Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Curr Med Res Opin 2006 22 : 2037 9.
23. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006 22 : 511 28.
24. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol- associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006 10 : 851 66.
25. Kalogirou M, Tsimihodimos V, Gazi I et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007 23 : 1169 76.
26. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005 21 : 959 69.
27. Ahmad I, Ruby E, Usman H et al. Ezetimibe-induced acute pancreatitis. South Med J 2007 100 : 409 10.
28. Fux R, Morike K, Gundel UF et al. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004 140 : 671 2.
29. Phillips PS. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004 141 : 649.
30. Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006 22 : 141 4.
31. Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy 2007 27 : 309 11.
32. Liu Q, Tobias H, Petrovic LM. Drug-induced liver injury associated with ezetimibe therapy. Dig Dis Sci 2007 52 : 602 5.
33. Perez-Calvo J, Civeira-Murillo F, Cabello A. Worsening myopathy associated with ezetimibe in a patient with McArdle disease. Q J Med 2005 98 : 461 2.
34. Panichi V, Manca-Rizza G, Paoletti S et al. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Biomed Pharmacother 2006 60 : 249 52.
35. Puthenparumpil JJ, Keough-Ryan T, Kiberd M et al. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005 37 : 1033 5.
36. Kohnle M, Pietruck F, Kribben A et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006 6 : 205 8.
37. Buchanan C, Smith L, Corbett J et al. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006 6 : 770 4.
38. Fellstrom B. Impact and management of hyperlipidemia posttransplantation. Transplantation 2000 70 : SS51 7.
39. Kiberd B, Keough-Ryan T, Panek R. Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant 2003 3 : 1393 9.
40. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997 63 : 331 8.
41. Gazi IF, Liberopoulos EN, Athyros VG et al. Statins and solid organ transplantation. Curr Pharm Des 2006 12 : 4771 83.
42. Jakulj L, Trip MD, Sudhop T et al. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J Lipid Res 2005 46 : 2692 8.
43. Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002 90 : 1092 7.
44. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003 24 : 729 41.
45. Davidson MH, Ballantyne CM, Kerzner B et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004 58 : 746 55.
46. Feldman T, Koren M, Insull W Jr. et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004 93 : 1481 6.
47. Ballantyne CM, Blazing MA, King TR et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004 93 : 1487 94.
48. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003 107 : 2409 15.
49. Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003 91 : 418 24.
50. Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003 24 : 717 28.
51. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002 40 : 2125 34.
52. Stein E, Stender S, Mata P et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004 148 : 447 55.
53. Ballantyne CM, Abate N, Yuan Z et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005 149 : 464 73.
54. Goldberg AC, Sapre A, Liu J et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004 79 : 620 9.
55. Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004 26 : 1758 73.
56. Landray M, Baigent C, Leaper C et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006 47 : 385 95.
57. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002 90 : 1084 91.
58. Davidson MH, Maccubbin D, Stepanavage M et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006 97 : 223 8.
59. Havranek JM, Wolfsen AR, Warnke GA et al. Monotherapy with ezetimibe causing myopathy. Am J Med 2006 119 : 285 6.
60. Simard C, Turgeon J. The pharmacokinetics of ezetimibe. Can J Clin Pharmacol 2003 10 (Suppl. A 13A 20A.
61. Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999 274 : 37161 8.
62. Evans AM. Membrane transport as a determinant of the hepatic elimination of drugs and metabolites. Clin Exp Pharmacol Physiol 1996 23 : 970 4.
63. Zetia [ezetimibe]. Mosby's Drug Consult [database online], 16th edn. Philadelphia : Elsevier, 2006.
64. Castro Cabezas M, de Bruin TW, de Valk HW et al. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993 92 : 160 8.
65. Phillips PS, Haas RH, Bannykh S et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002 137 : 581 5.
66. Phillips PS, Phillips CT, Sullivan MJ et al. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis 2004 177 : 183 8.
67. Lebo RV, Gorin F, Fletterick RJ et al. High-resolution chromosome sorting and DNA spot-blot analysis assign McArdle's syndrome to chromosome 11. Science 1984 225 : 57 9.
68. Jacobson TA, Armani A, McKenney JM et al. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007 99 : 47C 55C.
69. Stolk MF, Becx MC, Kuypers KC et al. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol 2006 4 : 908 11.
70. van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 2005 42 : 402 4.
71. Klett EL, Patel SB. Biomedicine. Will the real cholesterol transporter please stand up. Science 2004 303 : 1149 50.
72. Obermayer-Straub P, Strassburg CP, Manns MP. Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases. Can J Gastroenterol 2000 14 : 429 39.
73. Singh S, Loke YK. Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. Drug Saf 2006 29 : 1123 32.
74. Miltiadous G, Anthopoulou A, Elisaf M. Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP 2003 4 : 20 1.
75. Doherty E, Lumb PJ, Chik G et al. Ezetimibe-induced hyperlipidaemia. Int J Clin Pract Suppl 2005 : 3 5.
76. Brisson D, St-Pierre J, Santure M et al. Genetic epistasis in the VLDL catabolic pathway is associated with deleterious variations on triglyceridemia in obese subjects. Int J Obes (Lond) 2007 31 : 1325 33.
77. Elisaf MS, Nakou K, Liamis G et al. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 2000 11 : 1067 9.
78. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994 78 : 117 41.
79. Wagh A, Stone NJ. Commentary. Secondary causes of hypertriglyceridemia and pancreatitis. Clin Chim Acta 2003 332 : 21.
80. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007 176 : 1113 20.
81. Koshman SL, Lalonde LD, Burton I et al. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005 39 : 1561 5.
82. Bergman AJ, Burke J, Larson P et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 2006 46 : 328 36.
83. Kosoglou T, Statkevich P, Johnson-Levonas AO et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005 44 : 467 94.
84. Zetia [ezetimibe]. http://www.zetia.com (accessed 29 May 2007).
85. McCrindle BW, Urbina EM, Dennison BA et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007 115 : 1948 67.
86. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002 105 : 2469 75.
87. Wierzbicki AS, Doherty E, Lumb PJ et al. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005 21 : 333 8.
88. Kastelein JJ, Sager PT, de Groot E et al. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005 149 : 234 9.
89. http://www.merck.com/newsroom/press_releases/product/2004_1109_print.html (accessed 1 June 2007).
90. Rossebo AB, Pedersen TR, Allen C et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007 99 : 970 3.
91. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003 84 : S207 10.